EDINBURGH, Scotland, Sept. 5,
2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer, is proud to announce it has entered into
a collaboration agreement with Queen Mary University of
London (QMUL) to research the
therapeutic potential of gamma-delta T cells for the treatment of
mucosal infections. The collaboration recently received grant
funding from The Impact Fund arm of QMUL. TC BioPharm will be
working in conjunction with Dr. Neil
McCarthy's lab out of QMUL.
The project includes grant funding from The Queen Mary Impact
Fund (QMIF) to finance the study. QMIF provides highly flexible and
internally administrated funding to support knowledge exchange,
acceleration of impact, and bridges the gap between UKRI-funded
research (EPSRC, STFC, ESRC, and MRC) and benefits for society.
Dr. McCarthy's lab studies host–pathogen interactions at mucosal
surfaces, with a particular focus on gamma delta T-cells and their
role in gut barrier protection against microbial infection and
inflammation. The ultimate aim of this work is to understand how
gamma delta T-cell function becomes dysregulated in infectious and
inflammatory diseases and could potentially be restored by novel
agonist / antagonist immunotherapies.
"We are grateful for the support from the Queen Mary University
of London Impact Fund and appreciate Dr. McCarthy and his team
taking this initiative on with enthusiasm," said Bryan Kobel, CEO of TC BioPharm. "Dr. McCarthy's
lab is a leading institution in the gamma delta field focusing on
gut health and microbial infections, a great area of interest for
TCB. This is an exciting opportunity for our company and QMUL, the
collaboration is a good starting point for both groups with the
potential to extend into future engagements and asset spinoffs,
while simultaneously expanding the TCB-008 platform into new
indications. We believe the data set here and in future endeavors
will further showcase the therapeutic benefit of the gamma delta
T-cells centering around their role in immunotherapy's future.
"My team is excited about working with TC BioPharm to explore
the anti-microbial potential of γδ cell therapies," stated Dr.
McCarthy. "Our data suggests this could be a promising approach to
preventing gut barrier damage in context of mucosal infection and
inflammation. We look forward to learning more from this new
collaboration and exploring novel routes for translating γδ cell
potency into the clinic."
The QMUL Enterprise Investment Fund
The QMUL Enterprise Investment Fund has been launched, offering
the chance to invest in new technologies and innovations developed
by academics and students at QMUL. The Fund will offer tax reliefs
for individual investors under the government's tax efficient SEIS
and EIS schemes, and it is expected to appeal particularly to
alumni and other investors interested in investing in new
businesses arising from QMUL research and innovation. The Fund will
be managed by Javelin Ventures Limited, an experienced
FCA-regulated fund manager, and will benefit from a highly
experienced Investment Advisory Committee comprising respected
entrepreneurs and investors from across technology sectors.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the
use of CARs with gamma-delta T cells and owns our manufacturing
facility to maintain cost and product quality controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-grant-funding-in-collaboration-with-queen-mary-university-of-london-qmul-301916032.html
SOURCE TC BioPharm